The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition
Authors
Keywords
Breast Cancer, Tamoxifen, Aromatase Inhibitor, Adenoid Cystic Carcinoma, Invasive Lobular Carcinoma
Journal
Breast Cancer
Volume 23, Issue 3, Pages 329-342
Publisher
Springer Nature
Online
2016-02-24
DOI
10.1007/s12282-016-0670-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial
- (2016) Tsutomu Takashima et al. LANCET ONCOLOGY
- Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
- (2015) Prudence A. Francis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor–positive, lymph-node–negative early-stage breast cancer in Japan
- (2014) Hideko Yamauchi et al. BMC HEALTH SERVICES RESEARCH
- Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies
- (2014) Matthew P. Goetz et al. JNCI-Journal of the National Cancer Institute
- Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
- (2014) Stefan Aebi et al. LANCET ONCOLOGY
- Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
- (2014) Olivia Pagani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of efficacy of 95-gene and 21-gene classifier (Oncotype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients
- (2013) Yasuto Naoi et al. BREAST CANCER RESEARCH AND TREATMENT
- CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial
- (2013) V. O. Dezentjé et al. BREAST CANCER RESEARCH AND TREATMENT
- CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
- (2013) M A Province et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- CYP2D6 Genotype and Tamoxifen Activity: Understanding Interstudy Variability in Methodological Quality
- (2013) M J Ratain et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer
- (2013) D. Berry JNCI-Journal of the National Cancer Institute
- Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials
- (2012) J. Huober et al. ANNALS OF ONCOLOGY
- 1st International consensus guidelines for advanced breast cancer (ABC 1)
- (2012) F. Cardoso et al. BREAST
- A review of adenoid cystic carcinoma of the breast with emphasis on its molecular and genetic characteristics
- (2012) Semir Vranic et al. HUMAN PATHOLOGY
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) James M. Rae et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Meredith M. Regan et al. JNCI-Journal of the National Cancer Institute
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- (2012) Christina Davies et al. LANCET
- Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
- (2011) Michael Gnant et al. LANCET ONCOLOGY
- Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients
- (2010) Yasuto Naoi et al. BREAST CANCER RESEARCH AND TREATMENT
- Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
- (2010) Kazuma Kiyotani et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N·SAS-BC 01 trial and CUBC trial)
- (2009) Yasuo Ohashi et al. BREAST CANCER RESEARCH AND TREATMENT
- Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study
- (2009) Y Park et al. BRITISH JOURNAL OF CANCER
- Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen
- (2009) Masatsugu Okishiro et al. CANCER
- No Association Between CYP2D6*10 Genotype and Survival of Node-negative Japanese Breast Cancer Patients Receiving Adjuvant Tamoxifen Treatment
- (2009) T. Toyama et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Oral Uracil and Tegafur Compared With Classic Cyclophosphamide, Methotrexate, Fluorouracil As Postoperative Chemotherapy in Patients With Node-Negative, High-Risk Breast Cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial
- (2009) Toru Watanabe et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer
- (2009) Stewart J. Anderson et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
- (2009) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
- (2009) Kathy S Albain et al. LANCET ONCOLOGY
- Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer
- (2009) Hyman B. Muss et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment
- (2008) Y. Xu et al. ANNALS OF ONCOLOGY
- Clinicopathologic characteristics of invasive lobular carcinoma of the breast
- (2008) Enrico Orvieto et al. CANCER
- A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Locoregional Relapse of Breast Cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37
- (2008) Irene L. Wapnir et al. Clinical Breast Cancer
- Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study
- (2008) Ahmed Badawy et al. FERTILITY AND STERILITY
- Distinct Clinical and Prognostic Features of Infiltrating Lobular Carcinoma of the Breast: Combined Results of 15 International Breast Cancer Study Group Clinical Trials
- (2008) Bernhard C. Pestalozzi et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started